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ABSTRACT 
A 51-year-old man with Behçet’s disease complained of fever,
dry cough and dyspnea during exertion. Chest CT showed
ground glass opacities with interstitial septal thickening in
both lungs. Bronchoalveolar lavage (BAL) revealed amorphous
and lipoproteinaceous material that was periodic acid-Schiff
(PAS) stain positive. Transbronchial biopsy specimen demon-
strated PAS positive alveolar eosinophilic material consistent
with pulmonary alveolar proteinosis. Serum anti-granulo-
cyte-macrophage colony stimulating factor (GM-CSF) anti-
body was negative. Recent studies have reported anti-GM-
CSF not present in the the serum of patients with secondary
pulmonary alveolar proteinosis (PAP) but they have not
reported so in patients with idiopathic PAP. We report a case
of alveolar proteinosis in the setting of Behçet’s disease with
spontaneous remission.  
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RIASSUNTO 
Un paziente maschio di 51 anni con malattia di Behçet riferiva
febbre, tosse secca e dispnea da sforzo. Alla TAC torace si evi-
denziavano opacità a vetro smeriglio con inspessimento dei
setti interstiziali in entrambi i polmoni. Il lavaggio broncoal-
veolare ha recuperato materiale amorfo, lipoproteinaceo, po-
sitivo alla colorazione con acido periodico-Schiff (PAS). La
biopsia transbronchiale dimostrava materiale alveolare eosi-
nofilo PAS positivo, compatibile con una proteinosi endoal-
veolare polmonare. Il tasso serico di anticorpi anti fattore sti-
molante la colonia dei granulociti e macrofagi umani (GM-
CSF) era negativo. Studi recenti hanno riportato l’assenza di
anti-GM-CSF nei pazienti con proteinosi endoalveolare se-
condaria, a differenza di quanto avviene nelle forme idiopati-
che. Viene qui descritto un caso di proteinosi alveolare in cor-
so di malattia di Behçet a remissione spontanea.
Parole chiave: Anticorpo anti fattore stimolante la colonia dei
granulociti e macrofagi umani, malattia di Behçet, proteinosi
endoalveolare.  
INTRODUCTION
Pulmonary alveolar proteinosis (PAP) is a rare disor-
der characterized by abundant accumulation of sur-
factant within the alveoli [1]. The disease presents
clinically in one of three forms: congenital, primary
acquired (idiopathic), or secondary [2,3]. The
acquired or idiopathic form accounts for more than
90% of all cases and is believed to be caused by
autoantibodies targeting granulocyte-macrophage
colony stimulating factor (GM-CSF) [4,5].
Secondary PAP develops in association with hema-
tological malignancies, chronic pulmonary infec-
tions, inhalation exposure, and HIV infection [2,3].
Recent studies have reported the detection of neu-
tralizing autoantibodies against GM-CSF in the
serum as well as BAL fluid of patients with idiopath-
ic PAP which suggests that GM-CSF may be a sero-
logic marker for idiopathic PAP [4,5]. Spontaneous
remission may occur in up to one third of the
patients [6]. In this paper, we report a case of sec-
ondary alveolar proteinosis associated with
Behçet’s disease, which was diagnosed by BAL
findings and lack of circulating anti-GM-CSF anti-
body, with spontanoeus resolution.  
CASE PRESENTATION
A 51-year-old man with stable Behçet’s disease
reported dry cough and dyspnea upon exertion
which had developed three weeks earlier. Past med-
ical history was unremarkable except for Behçet’s
disease diagnosed at the age of 45. There was no
history of occupational or exogenous exposure. The
patient commenced on topical steroid and
cyclosporine treatment for one month that was
completed two weeks before admission for uveitis.
Physical examination revealed fever (37.4°C),
papular skin lesions and fine rales at the base of
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both lungs. Laboratory data on admission were as
follows: hemoglobin, 13.1 g/dl; hematocrit, 40.2%;
leukocytes, 6400/mm3; platelets, 223,000/mm3;
erythrocyte sedimentation rate, 42 mm/h; and C-
reactive protein, 12.4 mg/dl. Serum biochemistry
and urinanalysis were normal. Chest x-ray showed
ground glass opacification and interstitial pattern
particularly in the right lung. Arterial blood gases at
room air were as follows: pH: 7.42, pO2: 74 mm
Hg, and pCO2: 36.8 mm Hg. Pulmonary function
tests were normal: forced ventilatory capacity
(FVC), 3700 mL, 96% predicted; forced expiratory
volume in 1 second (FEV1), 2800 mL, 91% predict-
ed; diffusion lung capacity (DLCO), 82% predicted.
CT scan of the chest revealed ground glass opacifi-
cation of alveolar spaces with thickening of inter-
lobular and intralobular septa typical of the crazy
paving pattern (Figure 1). The blood cultures were
negative. Serologies for cytomegalovirus, respiratory
syncytial virus, adenovirus, influenza, legionella and
Mycoplasma pneumoniae were also negative.
Empirical treatment with moxifloxacin was instituted.
Bronchoscopy was performed because the fever
persisted. The bronchial system was normal with no
endobronchial pathology and no sign of infection.
Bronchoalveolar lavage (BAL) fluid was cloudy in
appearence. BAL differential cytology showed the
composition to be 74% macrophages, 21% neu-
trophils, and 5% lymphocytes. Light microscopic
examination of the fluid showed large amounts of
amorphous, lipoproteinaceous material that was
periodic acid-Schiff stain (PAS) positive (Figure 2).
Smear, special stains, culture of the BAL fluid, and
tissue were negative for tuberculosis, bacteria,
Pneumocystis carinii, fungi or malignant cells.
Histology of the transbronchial biopsy specimen
demonstrated a PAS-positive intra-alveolar
eosinophilic material consistent with PAP. Previous
studies have reported anti-GM-CSF antibody as
being present in the serum of patients with idio-
pathic PAP. Anti-GM-CSF antibodies were not
detected in the serum and BAL fluid. Based on these
findings the patient was diagnosed as secondary
PAP associated with Behçet’s disease. While the
patient was followed as an outpatient at our depart-
ment his clinical status was stable with progressive
recovery of dyspnea and cough. Physical examina-
tion returned to normal. Chest CT performed four
weeks later revealed complete resolution of the
ground glass opacification and septal thickening
(Figure 3). No recurrence was observed during the
follow up period.
DISCUSSION
PAP is a rare disorder characterized by abundant
accumulation of phospholipids and proteinaceous
material within the alveoli of the lungs. Since this
disease was first described in 1958, fewer than 500
cases have been reported in the medical literature.
The great majority of these cases are of the acquired
variety. Advances in the cellular and molecular
FIGURE 1: CHEST CT DEMONSTRATING GROUND GLASS
OPACITIES WITH THICKENED INTERLOBULAR SEPTA IN BOTH
LUNGS, THE TYPICAL CRAZY PAVING PATTERN SEEN IN
PULMONARY ALVEOLAR PROTEINOSIS
FIGURE 3: CT OF THE CHEST SHOWING COMPLETE
RESOLUTION OF THE GROUND GLASS PATTERN AND
INTERSTITIAL THICKENING OF THE INTERLOBULAR SEPTA
FIGURE 2: EOSINOPHILIC MATERIAL IN THE ALVEOLAR
SPACES WITH SCATTERED ALVEOLAR MACROPHAGES AND






























6 basis of the disease have led to a better understand-
ing of the pathogenesis of PAP. The link between
GM-CSF and human idiopathic PAP was revealed
when anti-GM-CSF antibodies were detected in the
serum and BAL fluid of patients with the disease.
The idiopathic form accounts for more than 90% of
cases and is believed to be caused by autoantibod-
ies targeting granulocyte-macrophage-colony-
stimulating factor. In contrast, the role of GM-CSF in
secondary PAP is unclear [4,5]. Secondary PAP
develops in the setting of a predisposing factor such
as hematological malignancies, immunodeficiency
syndromes, chronic infection or immunosuppres-
sive medications [2,7,8]. 
PAP has only rarely been associated with auto-
immune diseases. In a review of over 400 published
cases of PAP, a diagnosis of Behçet’s disease coex-
isted in only one patient reported by Uchiyama et
al. [9]. We believe that the presence of alveolar pro-
teinosis may be underestimated because of three
factors. One, alveolar proteinosis associated with
Behçet’s syndrome may easily be missed as there
are no specific features of alveolar consolidation to
suggest the diagnosis. Second, the diagnosis can
only be made with confidence on the basis of high
resolution computed tomography (HRCT)
appearence. Third, correct stains are needed for
pathologic diagnosis. Consequently, alveolar pro-
teinosis may be overlooked or misdiagnosed as
another inflammatory disease such as pneumonia,
alveolar hemorrhage or drug reaction which are
common in the setting of autoimmune disease. 
The absence of anti-GM-CSF antibodies strongly
suggested that our patient had developed secondary
PAP in the setting of Behçet’s disease. The develop-
ment of PAP may have been associated with infec-
tion but there was no evidence of current or earlier
infection. Although few studies have described an
association between secondary PAP and prolonged
corticosteroid therapy, the effect of local steroid
treatment may be considered negligible for
immunosuppression as there are no data to suggest
immunosuppression due to short course local
steroid treatment. Furthermore, patients who
receive corticosteroid treatment for other conditions
do not develop alveolar proteinosis because only a
few studies have described an association between
secondary PAP and long-term corticosteroid thera-
py [10]. The predominant mechanism for alveolar
proteinosis in our patient was cycloserine induced
immunosuppression. Inhibition of CD4-T cells by
cyclosporine may have produced deficiency of
macrophage recruitment and phagocytosis causing
impairment of surfactant clearance in this case.
Autoimmune disease and vasculitis may also have
contributed to the development of alveolar pro-
teinosis to a variable extent by unknown mecha-
nisms. Although alveolar proteinosis may run a fatal
course, spontaneous recovery may also occur [1,6].
To our knowledge, this is only the second reported
case of secondary PAP associated with Behçet’s dis-
ease and the first case of a spontaneous remission. 
Our patient draws attention to the fact that second-
ary alveolar proteinosis with spontaneous resolu-
tion may occur in the setting of Behçet’s disease.
Therefore, unnecessary diagnostic interventions or
treatment modalities for secondary alveolar pro-
teinosis associated with Behçet’s disease should be
reconsidered in stable patients. Further case data-
base and multicenter trials are needed to establish
the real incidence and prognosis of alveolar pro-
teinosis in Behçet’s disease. 
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